4 ms·
The problem starts with the time between patent award and regulatory approval limiting the commercial exclusivity. This has driven big pharma to patent manufact
by retcore 4y ago
The problem starts with the time between patent award and regulatory approval limiting the commercial exclusivity. This has driven big pharma to patent manufacturing processes instead of the compounds. If I understand it correctly from memory the Ritalin availability crisis was a example of process patent reengineering.
Edit: was not is.
- pbhjpbhj 4y agoThere is a system called supplementary protection certificates (SPCs) that gives an extension you the monopoly period to account for regulatory approval periods. https://en.wikipedia.org/wiki/Supplementary_protection_certificate https://en.wikipedia.org/wiki/Supplementary_protection_certi... (I haven't checked this link).